TY - JOUR
T1 - Genomic-scale prioritization of drug targets
T2 - The TDR Targets database
AU - Agüero, Fernán
AU - Al-Lazikani, Bissan
AU - Aslett, Martin
AU - Berriman, Matthew
AU - Buckner, Frederick S.
AU - Campbell, Robert K.
AU - Carmona, Santiago
AU - Carruthers, Ian M.
AU - Chan, A. W.Edith
AU - Chen, Feng
AU - Crowther, Gregory J.
AU - Doyle, Maria A.
AU - Hertz-Fowler, Christiane
AU - Hopkins, Andrew L.
AU - McAllister, Gregg
AU - Nwaka, Solomon
AU - Overington, John P.
AU - Pain, Arnab
AU - Paolini, Gaia V.
AU - Pieper, Ursula
AU - Ralph, Stuart A.
AU - Riechers, Aaron
AU - Roos, David S.
AU - Sali, Andrej
AU - Shanmugam, Dhanasekaran
AU - Suzuki, Takashi
AU - Van Voorhis, Wesley C.
AU - Verlinde, Christophe L.M.J.
N1 - Funding Information:
The authors wish to acknowledge all of the investigators who provided the data in the TDR Targets database including those that participated in the survey on drug targets for Human African Trypanosomiasis (HAT survey) conducted during 2007. We would also like to acknowledge Brandeis University MS students P. Bais and B. Coflan for work on the association of targets with compounds; R. L. Stevens (Argonne National Laboratory) for providing data for gene essentiality in bacteria; K. Chaudhary and T. Carlow (New England BioLabs) for integrated C. elegans phenotype data; J. Sacchetini (Texas A&M) for information on known M. tuberculosis drug targets; and M. Schreiber (Novartis Institute for Tropical Diseases, Singapore) and J. Brown (GlaxoSmithKline) for input on integrating data on persistent expressed genes in dormant-stage M. tuberculosis infection. We would also like to acknowledge essential computational infrastructure and genome annotations made available through the OrthoMCL database (supported by the US National Institutes of Health; NIH); GeneDB (supported by the Wellcome Trust); Ensembl (supported by the European Bioinformatics Institute); and EuPathDB (supported by a Bioinformatics Resource Center contract from the US NIH/National Institute of Allergy and Infectious Diseases). The authors also gratefully acknowledge Pfizer Global Research and Development for sharing data related to druggability. This work was supported by grants from the United Nations Development Programme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases.
PY - 2008
Y1 - 2008
N2 - The increasing availability of genomic data for pathogens that cause tropical diseases has created new opportunities for drug discovery and development. However, if the potential of such data is to be fully exploited, the data must be effectively integrated and be easy to interrogate. Here, we discuss the development of the TDR Targets database (http://tdrtargets.org), which encompasses extensive genetic, biochemical and pharmacological data related to tropical disease pathogens, as well as computationally predicted druggability for potential targets and compound desirability information. By allowing the integration and weighting of this information, this database aims to facilitate the identification and prioritization of candidate drug targets for pathogens.
AB - The increasing availability of genomic data for pathogens that cause tropical diseases has created new opportunities for drug discovery and development. However, if the potential of such data is to be fully exploited, the data must be effectively integrated and be easy to interrogate. Here, we discuss the development of the TDR Targets database (http://tdrtargets.org), which encompasses extensive genetic, biochemical and pharmacological data related to tropical disease pathogens, as well as computationally predicted druggability for potential targets and compound desirability information. By allowing the integration and weighting of this information, this database aims to facilitate the identification and prioritization of candidate drug targets for pathogens.
UR - http://www.scopus.com/inward/record.url?scp=55349104084&partnerID=8YFLogxK
U2 - 10.1038/nrd2684
DO - 10.1038/nrd2684
M3 - Article
C2 - 18927591
AN - SCOPUS:55349104084
SN - 1474-1776
VL - 7
SP - 900
EP - 907
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 11
ER -
